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INTRODUCTION 
In our diagnostic virology laboratory, we test on average 1500 samples for HIV antibody/antigen 
each month, of which 0.6% produces problematic results. These problematic samples produce 
either weakly reactive screening and confirmatory results or, discrepant screening and 
confirmatory results. Both scenarios require additional tests to confirm HIV status thus 
increasing cost and turnaround time. There is a need to devise an optimal strategy within the 
laboratory to rapidly and easily manage these samples with minimal additional cost. 
The WHO recommends three HIV testing strategies. Strategy I ensures blood transfusion safety 
while strategies II and III are used for both surveillance and diagnostics in high prevalence and 
low prevalence areas respectively.1The 2010 National antenatal sentinel HIV  & syphilis 
prevalence study reported the South African HIV prevalence as 30.2%.2 There were 1.8 million 
new cases of HIV infection in Sub-Saharan Africa in 2011.3South Africa (SA) is a high 
prevalence country and therefore the national HIV testing guideline is based on strategy II.  The 
HIV screening and confirmatory strategy at Groote Schuur is based on these recommendations. 
Strategy I requires that only one highly sensitive test be performed and if the result is positive, 
the blood donation is discarded. Strategy II requires that an initial positive HIV test performed 
using either a rapid HIV test or ELISA be confirmed with a second rapid test or ELISA.  This 
strategy is recommended when testing asymptomatic patients in areas with a prevalence of 
greater than 10%; and symptomatic patients in areas with a prevalence of less the 30%.1 
Strategy III requires a third positive test to confirm HIV positivity in low prevalence areas.  
On multiple occasions low positive and indeterminate HIV results of unknown significance are 
obtained. The WHO guidelines do not provide guidance on resolving/clarifying such problematic 
results.  This project aims to characterize these low positive and indeterminate results in order 
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to determine the scenarios in which false positives not requiring further tests and true positives 
requiring further tests are more likely to occur. Some of these results are sent out as discrepant 
but likely false positive results as per national guideline and standard laboratory practice. 
However poor follow -up and repeat testing of the patients as requested by the laboratory, have 
made it difficult to determine which results were true false positives. False positive serology 
results occur when cross reactivity between patient antibody and antigen other than the source 
antigen occurs. This may occur in cases of immature immune systems, other infections and 
autoimmune diseases. Published clinical scenarios in which false positive HIV antibody results 
are produced are pregnancy, hypergammaglobulinemia4,tuberculosis, vaccination against 
influenza, receipt of tetanus immune globulin4  and systemic lupus erythematosis.5Reporting 
false positive results have far-reaching negative repercussions not only on the patient’s psyche 
but also impacts clinical practice and health systems. 6 
It is essential that we gain more insight into determining the significance of low positive HIV 
results in the different laboratory scenarios as this will guide pathologists in deciding whether 
more tests are required and, if so, which test will be the best choice. There are three additional 
tests, viz. the HIV viral load, the p24 immunoassay and the western blot, that can assist in 
confirming HIV status. These tests differ in assay principle, cost to patient (or the National 
Department of health) and duration of time required to perform the test. The HIV viral load costs 
the laboratory R89.76 per sample and the p24 assay costs R205.57 per sample to test. The 
DOH is charged R 155.65 per p24 and R 293.86 per HIV viral load test performed. An additional 
test request will add 24 hours to the time taken to produce an authorised result.  By determining 
the most appropriate additional confirmatory test, the cost to patient will be decreased, as 
unnecessary test requests will be reduced. Turnaround time required to release authorized 
results will also be reduced. Ultimately the confirmations of low HIV tests will be streamlined 





To establish a validated supplementary HIV testing protocol for the management of low positive 
HIV serology and discrepant screening / confirmatory HIV serology. 
 
METHODS 
The study will be a retrospective laboratory review. A search will be performed on the laboratory 
tool, the WSDisa database from 01 June 2012 to 31 July 2013 for all HIV screening serology 
results. The search will include all patients who had HIV screening tests performed at the 
Groote Schuur Virology laboratory during the period of 01 June 2012 to 15 June 2013. This 
includes patients who had samples referred to the laboratory from other institutions for 
resolution of discrepant results. 
 
Inclusion Criteria 
 Samples screened using the ARCHITECT (®) HIV Ag/Ab Combo assay with a result of 
less than 20 S/CO (signal/cut off ratio) and, 
 Had an OD result of less than 2.0 when confirmed using the Enzygnost® Anti-HIV 1/2 
plus assay 
In order to determine the true serological status of these patients, additional tests will be 
performed on the low positive samples based on the inclusions. The additional tests will be the 
Abbott RealTime® HIV-1 assay (viral load), the VIDAS®HIV P24 II (p24 antigen) and the BIO-
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RAD GS HIV-1 Western Blot. All included samples will have a p24 antigen and HIV viral load 
test performed. Western blot tests will only be performed on samples with positive Enzygnost 
confirmatory tests since no readable result can be expected on WB if antibody levels are below 
the Enzygnost cut-off. The HIV viral load will be performed, as viral RNA is the earliest 
detectable marker of HIV infection and thus will confirm positivity in patients with low positive 
serology in early infection where p24 antigen is not detectable yet or has been missed by the 
ARCHITECT (®) HIV Ag/Ab Combo assay related second window period (see assay description 
below).7 The p24 antigen assay will be performed in order to determine the scenarios in which 
the low positive screening result is a reflection of p24 antigen being produced. The western blot 
test will determine HIV status in cases of low positive screening and low positive confirmatory 
tests in order to exclude false positive results because of non-specific cross reactivity.  
 
Assays 
ARCHITECT (®) HIV Ag/Ab Combo assay 
This is a fourth generation HIV assay that detects the presence of the HIV p24 antigen as well 
as antibodies to HIV -1 and HIV -2 in human plasma and serum using chemiluminescent 
technology with the resultant reaction measured in relative light units8. A signal to cut-off ratio of 
equal or greater to one is regarded as positive. A ratio of less than one is negative. We regard 
samples lower than 20 S/CO as low positive. There is a possibility of a second window period 
when using the fourth generation assay at a point when the detectable p24 antigen decreases 
to below the limit of detection of the assay and antibody is not yet detected. 
Enzygnost® Anti-HIV 1/2 plus 
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This is an immunoassay that detects antibodies to antigen of HIV-1 and -2 bound to a microtitre 
plate. Enzyme bound conjugate binds to the bound antibody. The enzymatic activity of the 
bound conjugate results in a colour change when a chromogen is added, the intensity of which 
is proportional to the concentration of antibody present9. The results are reported as optic 
density (O.D.) 
Abbott Realtime® HIV-1 assay 
The RealTime® HIV-1 assay (Abbott Molecular, Des Plaines, IL) is real time PCR assay that 
detects HIV viral load in plasma samples. The assay is able to quantify virus over a range of 40 
to 107 RNA copies per ml.10 
VIDAS®HIV P24 II 
This immunoassay will be used to detect p24 antigen that is detectable in infected blood as 
early as three weeks post infection.  The antigen becomes undetectable as soon as all the p24 
form complexes with antibody and therefore is a measure of acute infection. This is a sandwich 
immunoassay with the antigen measured by fluorescence detection.11 
BIO-RAD GS HIV-1 Western Blot 
This is a qualitative assay that detects and identifies antibodies to HIV in human serum and 
plasma.  HIV-1 specific antibody binds to inactivated HIV antigen fixed onto nitrocellulose 
sheets.  A colour change reaction occurs allowing for the identification of bound antibody.12 The 
position and intensity of the bands are compared to reference strips. We will be using WHO 






For the sample size calculation, we assume that the information provided by current screening 
and confirmatory tests alone is most likely able to correctly identify the HIV status of the patients 
with discrepant or low positive results in 70% cases. With the addition of HIV viral load, p24 and 
Western Blot tests proposed in this study we would be able to correctly identify the HIV 
diagnosis 90% of the time. In order to reliably demonstrate this improvement 92 samples are 
required. 
Continuous variables will be summarized in median and interquartile range while categorical 
variables will be analysed as proportions/percentages with 95% confidence intervals. The 
sensitivity and specificity of each assay/combination of assays will be assessed and positive 
and negative predictive values will be determined. Chi-square test will be performed to 
determine the significance of difference between various testing methods and Receiver 
Operator Characteristics (ROC) curve analysis will be performed to determine the optimal cut-
off for screening HIV ELISA that would predict a true positive result. 
ETHICS 
This study will take the form of a laboratory review. All patient results and records will be treated 
as confidential by the investigator. Submission of this study to both the Human Research Ethics 
Committee and the Departmental Research Committee of Department of Clinical Laboratory 
Sciences at the University of Cape Town will be made. The study will be performed in 
accordance with the Declaration of Helsinki. 
This investigation will be primarily retrospective and therefore will pose not any risk to the 
patient. All investigations done contribute to the patient diagnosis and management. Results 
reported as discordant as per the national guideline may require additional tests in order to 
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complete the validation. In the event that the new results are contrary to the previously released 
results, the managing clinician/team will be contacted and amended results will be released, as 
is standard laboratory practice for any retrospectively discovered erroneous laboratory result.  
 
OUTPUT 
This project will be of practical use in the laboratory for the following reasons: 
 Decisions made to perform additional tests will be based on laboratory based evidence 
rather than the pathologist’s judgment. 
 Teaching registrars and technologists about HIV confirmation of low positive HIV results 
will be based on laboratory based evidence 
 Cost of confirming HIV status and turnaround time required to produce authorized 
results for low positive HIV screening results will be reduced. 
This project will be of value to other virology laboratories and clinicians as it will contribute to the 
management of low positive HIV results and will therefore be written up for publication. 
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ESTIMATED BUDGET (As per cost to laboratory) 
TEST COST (R) NUMBER TOTAL (R) 
p24 85 20 1700 
HIV viral  90 20 1800 
Western 





PART B: LITERATURE REVIEW 
 
 
Objectives of literature review 
 
Since the introduction of HIV diagnostic tests 1985, great technical advancement has 
occurred in this field necessitating the updating of HIV testing algorithms. The 
objective of this literature review was to track the evolution of diagnostic HIV assays 
and show how new developments affected the local and international diagnostic HIV 
screening and confirmatory guidelines. 
 
Literature search strategy 
 
Electronic databases as well as the Google search engine were used to conduct the 
literature search. The databases were PubMed and Google Scholar. The search 
terms used were HIV, human immunodeficiency virus, diagnostic tests, antibody 
antigen, viral load, western blot, discrepant or indeterminate HIV results, false 
positive, false negative, sensitivity, and specificity. More specific terms e.g. 4th 
generation ELISA, were used when a more detailed search was required. Articles 
from 1980 to 2013 were included as the historical perspective of HIV testing was 
reviewed as part of the manuscript. International and local data were included in the 
review and the references of citations were studied in order identify additional data. 
Citations were limited to English language and human studies.  
 
Summary and interpretation of literature, and its implications for the research 
 





Antibody Tests  
Commercial HIV diagnostic tests first became available in 1985 (Chappel et al. 
2009). Four generations of assays have been developed, the first 3 antibody based 
and the fourth antigen/antibody based (Murphy & Aitken 2011). Chappell et al. (2009) 
regarded the desire to increase sensitivity and reduce the window period for 
detection of antibodies as the primary motivation for the upgrade of these assays and 
also commented on the unacceptably high false positive rate. Naturally the rate of 
false positives produced is also dependent on the prevalence of the infection in the 
local area i.e. the lower the prevalence of disease, the lower the positive predictive 
value and therefore the higher rate of false positives (Kim et al. 2010; WHO 1997). 
This motivated the confirmation of positive screening results with a highly specific 
assay. The 1st and 2nd generation tests detected only IgG, the1st generation relying 
on crude or purified lysate and 2nd using synthetic polypeptide or carefully selected 
antigen produced by DNA technology (Murphy & Aitken 2011). Third generation 
assays were introduced in attempt to increase sensitivity and represented a change 
ELISA principle. These are sandwich assays, the plate well of which is coated with 
recombinant or synthetic peptides to which anti-HIV IgM and IgG bind. An enzyme 
linked to an HIV-antigen that binds to both anti-HIV IgG and IgM is added, a colour 
change reaction follows the addition of a substrate bound to an enzyme, and this 
shows that both IgM and IgG are detected. According to Daskalakis (2011), the 
detection of both the IgM and IgG reduces the window period by detecting low levels 
of antibody produced.  
 
ELISA tests may produce false positive results. Clinical conditions in which this can 
occur includes recent influenza vaccination, viral infections, autoimmune disease, 
renal failure and pregnancy and are thought to be caused by cross reacting 
antibodies (Mahajan et al. 2010; Erickson et al. 2006). Molecular mimicry may also 
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have a role to play as Bettaieb et al.(1996) demonstrated that there was cross 
reaction between gp129 and CD61 ( platelet gpIIIa ). 
 
Antigen/Antibody Assays  
The development of the 4th generation assay was again motivated by the desire to 
increase sensitivity and reduce the window period but in this case by detecting the 
p24 antigen which is detectable early in infection when not complexed to antibody 
(Weber et al. 1998).This assay is thus able to detect acute infection as well as 
established infection by detection of antibodies produced (Brennan et al. 2013). 
Unfortunately a disadvantage of the assay is that the result produced does not 
distinguish between the antigen and antibody component, and therefore requires 
additional steps for confirmation of either acute or established infection i.e. initially a 
p24 only assay is performed to confirm acute infection; if negative, a 2nd or 3rd 
generation assay needs to be performed to confirm established infection (Weber et 
al. 2002).In order to shorten the confirmation strategy, the development of a 5th 
generation assay should be considered which is able to differentiate between antigen 
and antibody. Another disadvantage is the potential risk of a second window period. 
A third of the binding capacity in these assays is reserved for antibody binding so 
there is the potential for reduced sensitivity of the p24 component (Gürtler et al. 
1998; Weber B, Meier T, 2002). In cases where there is an absence of detectable 
antibody and antigen the result may then be reported as falsely negative. A low 
positive result may be reported when minimal antibody or antigen is detected, and 
thereby creating the incorrect suspicion of a false positive result. There has to be a 
high index of suspicion of primary infection in cases where acute infection is clinically 
suspected but the 4th generation result is negative, or in the case of low positive 





P24 Antigen Assay  
Another enzyme immunoassay based test is the p24 monoassay (Fearon 2005). 
These standalone assays were developed in order to detect acute infections by 
detecting antigen in the era of antibody only assays (Chappel et al. 2009). Barletta et 
al. (2004) commented that the p24 assays are relatively insensitive and in some 
cases detecting as little as 50% of acute infection. They considered the assay of 
limited clinical utility (Barletta et al. 2004). Indeed, if the aim of performing the assay 
is to detect acute infection, 50% detection rate is poor. In the early days of 4th 
generation assay there was still some concern that the p24 component of these 
assay lacked sensitivity and were therefore regarded as unsuitable to replace the 
immunoassay. However newer 4th generation versions have shown improved 
sensitivity and are recommended instead of standalone assay (Ly et al. 2007).  
 
Rapid Tests  
Rapid HIV tests were introduced in order to make HIV tests more accessible and 
thereby identify and treat patients earlier (CDC 2003). Rapid tests are useful as the 
assays are disposable single use assays, can be stored at temperatures above 4o C , 
contain all the necessary reagents required to produce a valid results and are able to 
do so in less than 30 minutes (Branson 2007). They can therefore be used in a 
variety of locations including those without refrigeration. The rapid diagnostic assays 
are able to detect HIV using different sample types namely oral fluid, whole blood, 
plasma or serum (Daskalakis 2011) These assays are based on lateral flow, 
agglutination, or most recently, immunochromatographic principles (Constantine & 
Zink 2005). Situations where these assays are of particular benefit include 
occupational cases where post exposure prophylaxis can be initiated quickly, and 
women in labour where prevention of mother to child transmission can be initiated 
immediately (Constantine & Zink 2005). However these assays also result in new 
challenges as they are most often performed outside the laboratory environment, 
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performed by people with minimal laboratory skills, may perform the assay 
haphazardly as they become used to the simple procedure, and the interpretation of 
the results are subjective dependent on the means of detection, i.e. colour change or 
agglutination. This is evidenced by the findings of a study of the voluntary counselling 
and testing practices in primary health care clinics in South Africa that was performed 
by the SEAD group (SEAD 2011). They found multiple areas of concern, including 
inconsistent or absent quality assurance, specimen collection method (no further 
detail given) and shortened incubation time for result. The subjectivity of interpreting 
the colour change on the strip of the Determine HIV-1/2/O (Abbott Laboratories, 
Abbott Park, IL) resulted increased in increased false positive results (Gray et al. 
2007). Kilembe et al. (2012) tested a rapid antigen/antigen test but found that only 
23%of acute infections were detected.  
 
In 1992 the WHO recommended that countries consider using rapid tests as part of 
their testing strategy as, according to their weekly epidemiological record, the 
reliability of these results match or better those of commonly used ELISA and 
western blot (WHO 1992). This recommendation was reiterated in the 1997 
recommendation (WHO 1997). By 2007, the FDA had approved six rapid diagnostic 
test with both sensitivity and specificity greater 99% thereby supporting the WHO’s 
recommendation of using rapids test instead of ELISA tests (Branson 2007). 
However there have been findings published that recommend that all rapid tests be 
confirmed by conventional immunoassays (Fearon 2005). Pavie et al. performed a 
study published in 2010 which compared the sensitivities of five rapid tests used in 
hospital outpatient setting and found that assays using oral fluid had less sensitivity 
than fingerprick whole blood but that serum was more sensitive than the fingerprick 





Western Blot  
The western blot assay has long been a mainstay of HIV diagnostic testing, however 
sensitivity is poor compared to the newer assays. In comparison to the 4th 
generation assay (2.5 - 3 weeks) and 3rd generation assay (3-4 weeks), the western 
blot detects antibody at 5 weeks (Daskalakis 2011). The western blot was widely 
regarded as the gold standard assay for confirmation of the HIV positive screening 
results (Constantine & Zink 2005). This assay formed part of the first HIV testing 
recommendations introduced by the CDC in 1997as the confirmation assay following 
2 positive enzyme immunoassays (CDC 1997). However the sensitivity of this assay 
was brought into question as early as 1992, when the WHO recommended that this 
assay be replaced in the HIV screening strategies as the combination of two different 
ELISA and/or rapid test was found to have superior sensitivity to the enzyme 
immunoassay and western blot combination. (WHO 1992; WHO 1997). 
 
Besides relative insensitivity, the other issue facing this assay is that of indeterminate 
results. Different criteria for the interpretation of the HIV western blot assays have 
been proposed by various groups (CDC 1989) . Most criteria require reactivity to at 
least one envelope and one core protein, and any other non-specific bands are 
interpreted as indeterminate (Constantine & Zink 2005). There are several causes of, 
and conditions associated with indeterminate western blot results. These include 
early HIV infection, advanced AIDS, other retroviral infection, autoimmune disorder 
like systemic lupus erythematosus, kit design issues and assay process (Guan 
2007). In an attempt to improve on the unacceptably high indeterminate western blot 
results, Mahé et al. (2002) published diagnostic criteria for the African context 
consisting only of the gp160 and p31 bands that correctly classified 96% of samples. 
The possible production of indeterminate results; the time and labour intensive nature 
of the assay; the risk of cross-reaction between HIV-1 and -2 (Cárdenas et al. 2013), 
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and in the face of more accurate assays, this assay should no longer be deemed 
worthy of the gold standard title. 
 
HIV Viral Load Assays  
HIV viral load tests were introduced in the 1990s, initially as a research tool. 
Monitoring of HIV viral loads has now become routine in clinical practice (Mylonakis 
et al. 2001). Viral load assessment has been shown to be one of the best predictors 
of clinical progression of the infection as well as a measure of the effectiveness of 
antiretroviral drug use (Mendoza & Soriano 2014).In the past use assay was limited 
to the abovementioned situations (Fearon 2005). However focus has shifted to the 
role of RNA detection in the diagnosis of acute infection, and in confirmation following 
positive screening results. Acute HIV infection is defined as the time from HIV 
acquisition until seroconversion. The initial entry of the virus is followed by an eclipse 
phase of approximately 10 days when infection is not detectable by current assays 
(Cohen et al. 2010). HIV RNA is detectable from approximately one and a half weeks 
following infection by current nucleic acid tests while the current 4th generation 
ELISA assays are able to detect p24 antigen from two and half to three weeks post 
infection (Daskalakis 2011). It has been documented Fiebig et al. that the p24 
antigen only becomes detectable when the HIV viral load is 10 000 RNA copies/ml 
(Fiebig et al. 2003). Therefore there is a valuable period of time in which the infected 
patient is highly viraemic, risking spread of virus, and potentially could be treated but 
may be missed as the 4th generation screening result will most likely be falsely 
positive (Cohen et al. 2010). Brennan et al. (2013) recently published a study 
correlating the p24 sensitivity of ARCHITECT HIV Ag/Ab Combo assay with the RNA 
viral load. They found that the p24 antigen is detectable once the viral load has 
reached 58 000 copies/ml. While this study had several limitations, in particular the 
use of supernatant of HIV infected cultures cells, it does point out that some 
infections may be missed as a result of assay limitations. Naturally these findings 
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need confirmation using human samples. The HIV viral load has now been added to 
the latest CDC screening algorithm with western blot confirmation no longer a feature 
(CDC 2012; Branson 2010). 
 
HIV diagnostic algorithms 
 
It must be noted that it is impossible for a single algorithm to the cover all the 
scenarios that may occur in all settings and patients groups and therefore it is 
important to take the local setting into account when deciding upon a 
strategy.(Murphy & Aitken 2011). 
 
WHO Recommendations  
In 1992, the WHO released recommendations for the selection and use of HIV 
antibody tests in its Weekly Epidemiological Record.(WHO 1992) This record clearly 
sets out the objectives of HIV antibody testing. The objectives were 1) screening of 
blood and blood and blood product for transfusion safety, 2) the monitoring of HIV 
infection trends and prevalence for surveillance, 3) diagnosis of HIV testing, and 4) 
research for various HIV related studies. This document proposes strategies for HIV 
testing determined by the objectives of the test. By elegantly explaining the role of 
sensitivity, specificity and prevalence when choosing an assay, one is clearly able to 
understand how the strategies where decided upon. The three strategies of HIV 
testing proposed in this document are a) serum tested with one ELISA or rapid assay 
is considered positive or negative based on the result of this one test, b) all serum is 
tested with a rapid or ELISA test, and reactive serum is retested using a second 
ELISA or rapid test based on a different antigen preparation or test principle, and) 
similar to strategy II except that a third test is required to confirm serum positivity. 
The positive predictive value of a test will be low in a low prevalence setting and 
therefore a supplemental test is required to confirm results. These strategies form the 
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basis of the various international HIV testing algorithms. This document also 
discussed the relevance of equivocal results, recommending that a second blood 
sample is required a minimum of two weeks later and retested using the appropriate 
testing strategy. This is probably the origin of the clinical and laboratory practice of 
asking for a repeat specimen following the reporting of equivocal or indeterminate 
results. In my experience, this is not a good strategy as patients in our setting are 
often lost to follow up and the requested follow-up sample is never sent. 
 
The WHO updated this record in 1997 following the expansion of available antibody 
tests available (WHO 1997). Minor modifications were made to the three strategies 
previously recommended. This document clearly states that test combinations should 
be evaluated in the context where they will be used before wide-scale 
implementation. The preference for ELISA or rapid tests instead of western blot 
assay is reiterated with reduced sensitivity and cost being the motivating factors for 
this choice. Clear recommendations are made for the appropriate testing strategy for 
the local prevalence of infection. A diagrammatic version of the strategies suggested 
in the previous record clearly sets out the algorithm for HIV testing. 
 
CDC Recommendations  
The initial CDC recommendation for HIV testing considered a sample HIV positive if it 
had two reactive enzyme immunoassay results and a positive confirmation on 
western blot (CDC 1993). This recommendation was based on the 99% sensitivity of 
the enzyme immunoassays (EIAs) and 99% specificity on repeated EIAs in use at 
that time. The western blot assay had comparable sensitivity and high specificity 
when strict criteria determining result status was used (CDC 1993). Although the 
CDC presented revised guidelines in 2006, there was no change in testing strategy 
recommended but rather an attempt to increase the rate of earlier diagnosis by 
expanding testing to all health care settings, screening more people, employing 
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voluntary opt-out testing and removing the requirement for prevention counseling. It 
was only when the FDA approved the 4th generation assay and more sensitive rapid 
tests that differentiated between HIV-1 and -2 were developed, that a change in the 
actual testing strategy was proposed (Ginocchio et al. 2011). The new recommended 
testing algorithm includes screening all samples with a 4th generation assay or if not 
available, a 3rd generation assay. If the result is negative it is accepted as negative, 
but if positive the sample needs to be tested using an point of care assay that 
differentiates between HIV -1 and HIV-2,viz. the Bio-Rad Multispot® Rapid HIV-
1/HIV-2 Test, the only FDA approved test currently (Torian et al. 2011). If that result if 
negative or indeterminate, an HIV RNA test is required (CDC 2012). These new 
recommendations no longer include the western blot assay as confirmatory assay 
and do not include the standalone p24 immunoassay. The emphasis of this algorithm 
is on high sensitivity at screening so that early and established infections are not 
missed as the risk of rare false positive results that will be resolved by further testing 
(CDC 2012). See appendix B for algorithm. 
 
A cost and outcomes study comparing the previous recommended CDC HIV 
diagnostic algorithm and the newer one (Hutchinson et al. 2013). They found that for 
specimens that were HIV positive, the lab costs for the newer algorithm were 
cheaper than the preceding algorithm in general which they attributed to the high cost 
of the western blot assay recommended in the earlier assay. As the new guidelines 
recommended 3rd or 4th generation screening assay, the cost of using 4th 
generation assays was more expensive but detected 10 / 50 000 more infections. 
Therefore they believed the extra cost may be justified. In the South Africa context, 
where the prevalence and incidence are higher, use of a 4th generation assay and 
RNA viral load detection would be justified in terms of cost particularly regarding 
timeous diagnosis of infection, and of preventing the spread of new infections by 
means of early diagnosis.. Minimal comment is made by Hutchinson et al. about the 
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use of the high cost viral load in indeterminate cases. It may be too soon after the 
introduction of the new recommendations and therefore the sample size is not yet 
large enough. Perhaps it’s too early following its introduction and therefore the 
sample size is not large enough. In light of this new algorithm, further studies will now 
be possible to determine the cost-effectives of using RNA tests in the diagnosis of 
HIV. 
 
UK Recommendations  
The Health Protection Agency in the United Kingdom (UK) similarly recommends that 
samples are screened by a 4th generation assay; positive samples undergo a 
second test by the same assay or one of equivalent sensitivity. A second sample is 
requested for final confirmation but no mention of assay type is made. Negative 
samples are managed according to the clinical history i.e. if symptomatic, repeat in a 
week; if not regular screening recommended. Indeterminate samples are managed 
according to local policy (Health Protection Agency 2012). The UK algorithm does 
not recommend HIV viral load directly but it seems as though there is an opening for 
it be used under the umbrella of local guidelines. See appendix C for algorithm. 
 
South African Recommendations 
The South African National HIV counselling and testing policy guidelines are based 
the WHO recommendations and include screening with rapid tests and confirmation 
of a positive result with a second rapid test. Indeterminate results are referred for 
ELISA at the local laboratory. If that result is positive, the sample is reported as 
positive and if the result is negative, it is reported as negative (National Department 
of Health 2010). No provision is made for samples that might be indeterminate or 
discrepant in a district or academic laboratory setting where 4th generation, p24 




Identification of gaps or needs for further research 
 
Currently the most sensitive ELISA assay is the 4th generation assay but there is a 
need for a 5th generation ELISA assay that will be able to differentiate between 
antigen and antibody detected. This will simplify the strategy for confirmation of 
infection by showing detecting whether it’s an acute or established infection at 
screening. Once the validity of the new algorithm is assured, it will then be possible 
to create a protocol for confirmation with an HIV viral load for acute infection and an 
antibody confirmation assay for the antibody positive samples. 
 
There is a paucity of local publications on the validation of the 4th generation ELISA 
assays in the South African population. It will be useful to know the rate of false 
positive and false negative results of these assays, particularly as the prevalence of 
HIV is the highest in our setting and every attempt needs to be made to detect acute 
infection in order to stem the tide of new infections. Removal of the potential second 
window period, that may produce false negative results, is therefore of clinical 
importance. It will also be useful to obtain an estimate of what the 4th generation 
ELISA S/CO cut-off is for samples that are more likely to be falsely positive as this 
will reduce the costs as less unnecessary tests will be performed. A biological 
window when infection is not detectable will always exist this should be kept in mind. 
The proposed new research can then be used to make recommendations on 
strategies to deal with low positive or discrepant serology results, as there is a lack of 
provision for what should be done in these cases in the South African guidelines. 
 
More publications are necessary on the utility of the standalone p24 assay 
particularly in terms of sensitivity in our populations and whether performing a HIV 
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viral load on all the samples that are antibody negative on confirmation will be cost 
effective and of clinically utility. 
 
Screening for HIV-2 is not part of the South African guidelines and studies are 
required to determine the prevalence particularly as migration from rest of Africa to 
South Africa continues. High prevalence of HIV-2 infection is a potential reason for 
discrepant HIV diagnostic test results as the 4th generation assay is able to detect 
but not differentiate between the two virus while current molecular method only 
detect HIV -1. A high prevalence of HIV-2 will motivate for inclusion of HIV-1 and 
HIV-2 differentiation in the South African national guidelines. 
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Weakly reactive or low positive and discrepant HIV serology results across different 
platforms are common diagnostic dilemmas in virology laboratories. The HIV viral load, p24 
immunoassay and western blot are among tests performed to ascertain the true HIV status 
of problematic samples, but the lack of local standardised algorithms means that resolving 
these dilemmas is resource intensive. This study aimed to refine our HIV testing algorithm, 
through examining the performance of each of the adjunct HIV diagnostic assays in our 
routine laboratory setting. Our objective was to minimise cost and delay in providing the best 
possible result to the patient. Of the 48 weakly reactive samples examined, 24 (50%) were 
found to be true positive. The routine 3rd generation confirmatory assay lacked both 
sensitivity (72%) and specificity (91%) in this scenario. The p24 assay lacked sensitivity 
(37%) while the HIV viral load assay showed excellent sensitivity (100%) and specificity 
(100%). ROC analysis suggests by using low and high cut-offs, one can achieve good 
sensitivity or specificity respectively, thereby informing the correct subsequent testing 
strategy. The poor sensitivity of the p24 and the limited utility of western blot assay points 
toward using HIV viral load as the optimal diagnostic tool when confirming weakly reactive 
HIV serology.  
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1. Introduction  
The diagnostic virology laboratory at Groote Schuur Hospital uses a fourth generation HIV 
ELISA assay to screen on average 1500 samples for HIV antigen/antibody monthly. 
Approximately 0.6% of the samples are either weakly reactive or have discrepant 
confirmatory results. These scenarios are diagnostic dilemmas for both pathologist and 
clinician and require additional tests to be performed in order to confirm HIV status. The 
increased turnaround time and cost to the patient or government necessitates an optimised 
strategy within the laboratory to rapidly and easily manage these samples with minimal 
additional cost. Current practice involves screening with a 4th generation ELISA assay and 
then if positive, confirmation with a 3rd generation ELISA assay. The screening 4th 
generation ELISA and confirmatory 3rd generation can sometimes produce low positive and 
discrepant results. In this scenario the individual pathologist relies on their experience to 
determine if an additional test is required and if so, which test to request.  
Currently it takes 6 working hours to produce a positive HIV serology result and the cost to 
client is R99.36. If additional tests are required, the turnaround time can increase by at least 
one working day to more than a week dependent on the tests requested; and the cost can 
increase from an additional R161.88 (p24 test) to as much as R1145.27 (p24 + HIV viral 
load + western blot). See Table.1 below for costs of tests to the Department of Health (DoH). 
The specifications of the tests and their role in HIV testing will be described below. 
Test Cost to Department of Health  
HIV 4th gen EIA R 49.68 
HIV 3rd gen EIA R 49.68 
HIV p24 EIA R 161.88 
HIV viral load R 305.61 
HIV WB R 578.42 
       Table.1 Cost of tests to the Department of Health (Source: NHLS price list 7 February 2014). 
In an attempt to streamline HIV diagnostic testing internationally, the WHO in 1997, 
recommended three HIV screening strategies (WHO 1997). The recommendations are 
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currently still in place. The choice of strategy is dependent on the objective of the test. 
Strategy I ensures blood transfusion safety and is recommended in symptomatic patients in 
settings where the prevalence is greater than 30% while strategies II and III are 
recommended for both surveillance and diagnostics in high prevalence and low prevalence 
areas respectively (WHO 1997). South Africa currently follows the strategy II 
recommendations as it is regarded as high prevalence country. As of mid-2013, HIV 
prevalence in South Africa was 10.0% with certain sectors of the population having a 
prevalence as high as 17.4 % (women aged 15-49) (Statisitics South Africa 2013). However 
the national prevalence was reported as much higher among antenatal women at 24.9% 
(95% CI: 28.7% -30.2%) in 2009 (National Department of Health 2010). 
Strategy I requires that blood donation specimens be discarded after a single positive result 
is produced using a highly sensitive assay. Strategy III requires a third positive test to 
confirm HIV positivity in low prevalence areas. Strategy II requires that an initial HIV screen 
is performed and if positive, confirmed with another rapid HIV test or ELISA. This strategy is 
recommended for use in countries with greater than 10% prevalence in asymptomatic 
patients, and equal to or less than 30% in symptomatic patients. The South African 
recommended serial HIV testing algorithm is based on this strategy (see Appendix D) and 
hence the screening and confirmatory strategy used at Groote Schuur Hospital is based on 
these guidelines (National Department of Health 2010). These guidelines make provision for 
discrepancies between the initial two tests which are usually rapid tests performed at local 
clinics, by recommending that those samples be sent to laboratories for ELISA tests but 
does not make provision for discrepancies or indeterminate results following ELISA tests in 
those laboratories. 
The CDC introduced new guidelines in 2010, which recommends screening with a 4th 
generation assay, followed by discrimination of HIV-1 and -2 for reactive samples, with 
confirmation of indeterminate results with HIV viral load (Branson & Mermin 2011; CDC 
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2012). The development of the new algorithm was motivated by the lack of sensitivity of the 
p24 assays and western blot as well as the increased sensitivity and availability of the HIV 
viral load assays (Murphy & Aitken 2011). 
When cases of low positive or indeterminate results of unknown significance are obtained 
there isn’t any clarity within the WHO guidelines or within the South African testing algorithm 
on how to manage the situation. The aim of this study was to determine how to differentiate 
between true and false positives, in order to guide laboratory staff in decision-making. 
Additionally, the study aimed to determine whether the semiquantative 3rd generation ELISA 
optic density result had bearing on a true positive result as well as whether any particular 
test stood out as the optimal test to be used consistently in an algorithm aimed at 
determining true HIV status. 
HIV diagnostic tests are currently serology based tests detecting antibody or antigen and 
molecular tests detecting viral nucleic acid. These tests were first introduced in 1985 and 
evolving technologies have led to great advances (Constantine & Zink 2005). In our setting 
we use a 4th generation HIV ELISA assay which detects both early appearing p24 antigen 
and antibody, reducing the window period and allowing for detection of early and established 
infections (Chavez et al. 2011). The assay does not differentiate between the antigen and 
the antibody (Cohen et al. 2010). There is a rare phenomenon reported for this assay, 
namely the second window period, during which the p24 antigen is no longer detectable 
having complexed with antibody and the free antibody is still below the lower of detection of 
the assay, potentially allowing for false positive results (Meier et al. 2001; Speers et al. 
2005). The advantage of using a 3rd generation ELISA as the confirmatory assay is that 
negative results may indicate an acute infection where only p24 was detected in the 4th 
generation screening assay. This early infection scenario therefore requires additional 
confirmation with the p24 mono-immunoassay, or subsequent samples to demonstrate 
seroconversion. The p24 assay, however, has been documented as having inferior 
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sensitivity compared to HIV RNA detection, risking false negative results. Therefore the HIV 
viral load assay, although not licensed for HIV diagnosis, is used to confirm acute cases of 
HIV when antibody is undetectable and the viral load high (Cohen et al. 2010). Additionally, 
pathologists use the ability of the assay to detect RNA as a diagnostic test in the diagnostic 
dilemmas described above. In these cases the qualitative result is interpreted as 
positive(pos), negative (neg) or indeterminate, dependent on the range of the numerical 
result (neg being lower than detectable levels, indeterminate being greater than LDL but less 
the 1000 RNA copies/ml, pos greater or equal to 1000 RNA copies/ml). Naturally the 
implications of false negative tests are immense as this will result in delayed access to care 
with the resulting health implications and unwitting spread of disease to partners and 
children. HIV viral load testing is also used to confirm established infection as this assay is 
licensed for routine HIV viral load measurement in response to antiretroviral therapy. The 
previous gold standard for HIV confirmation is the western blot assay which fell out favour 
because of the superior sensitivity and specificity of the newer screening tests (Murphy & 
Aitken 2011). This assay is still used in our setting when serology and molecular tests 
remain inconclusive. 
It is the responsibility of the diagnostic laboratory to best determine whether positive results 
are true as misinterpretation can lead to incorrect clinical management decisions and 
psychological harm. False positive serology can result when cross reactivity occurs i.e. when 
non-specific binding occurs between the antigen used in the assay and proteins (other than 
the required HIV antibody) in the patient’s serum (Tate & Ward 2004). The clinical causes of 
false positive HIV serology include recent influenza vaccination, incidental viral infections, 
autoimmune disease, renal failure, cystic fibrosis, multiple pregnancies, blood transfusions, 
liver disease, intravenous drug abuse, haemodialysis, or vaccinations against hepatitis B 
and rabies (Mahajan et al. 2010; Erickson et al. 2006). It is therefore imperative that clinical 
history is taken into account when deciding on the validity of a result. The negative 
repercussions of reporting false positive results on the patient’s psyche and health, as well at 
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the impact on clinical practice and health systems, should not be underestimated. In a study 
performed by Médecins Sans Frontières, 47/326 (14%) people were found to be erroneously 
diagnosed and the average time spent on antiretroviral therapy by those misdiagnosed was 
484 days (Shanks et al. 2013). The aforementioned study was performed in a resource 
limited setting therefore, on a programmatic level, the reporting of incorrect results 
represented a considerable waste of resources and motivated for a change in HIV testing 
algorithm. False negative 2nd and 3rd generation ELISA results have been attributed to 
subtype incompatibility, recent infection or in some cases no inherent can be found (Evans 
et al. 1997; Preiser et al. 2000). 
The aim of this study was to establish a validated supplementary HIV testing protocol for the 
management of low positive HIV screening and discrepant screening / confirmatory HIV 
serology. 
2. Materials and method  
2.1 Samples and source population 
This study was a descriptive study based on a retrospective cohort of samples. The source 
of study samples was an archive of recent HIV serology serum samples from the National 
Health Laboratory Service (NHLS) virology laboratory at Groote Schuur Hospital. A search 
was performed on the laboratory tool, the Disa*Lab database for all HIV serology results 
from 01 June 2012 to 31 July 2013. The study was performed at a diagnostic pathology 
laboratory which provides a HIV diagnostic service for a tertiary academic hospital, and 
receives referrals from primary and secondary level health care facilities across the Western 
Cape Province. The referred samples often had preceding equivocal or indeterminate HIV 
rapid tests or other HIV screening ELISA results. A search of the Groote Schuur Hospital 
NHLS virology laboratory database for HIV screening serology was performed using the 
laboratory information system software. 
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In order to assess a range of weakly reactive result without testing a large number of true 
positive samples, an OD of 20 was chosen as low positive based on local pathologist 
experience. Samples were included if they met the inclusion criteria of a 4th generation 
screening ELISA assay result with a signal/cut off ratio (S/CO) of less than 20; and an optical 
density (OD) result of less than 2 when confirmed with the 3rd generation confirmatory 
assay. In order to determine the true status of indeterminate and discrepant results, 
additional HIV diagnostic tests, namely the p24 immunoassay, HIV viral load and western 
blot assay were performed on remaining samples (see explanation for determination of gold 
standard below).  
2.1.1 Ethics 
Approval for performing this study was obtained from the University of Cape Town Human 
Research Ethics Committee (HREC REF: 458/2013). 
 
2.2 Assays  
The ARCHITECT® HIV Ag/Ab Combo assay, a fourth generation dual sandwich EIA, was 
the screening assay used in this study to detect and p24 antigen as well as antibodies to 
HIV-1 and HIV-2 in human plasma or serum (Abbott Diagnostics 2010). Anti-HIV-1/2 
antibody and p24 antigen in serum bind to HIV antigen and monoclonal anti-p24 antibody on 
microparticles. After washing, acridinium-labelled conjugate binds to bound antigen/antibody. 
A chemiluminescent reaction ensues, the result of which is measured in relative light units 
and reported as a signal to cut-off ratio (S/CO). A signal to cut-off ratio of greater than or 
equal to 1 is regarded as positive and a ratio of less than 1 is negative. The range of S/CO 
results reported by the instrument is 1 to 999. 
The confirmatory 3rd generation sandwich ELISA used was Enzygnost® Anti-HIV 1/2 Plus, 
which detects antibodies to HIV-1 and -2 antigen bound to a microtitre plate (Dade Behring 
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2004). The enzymatic activity of the bound conjugate results in colour change when a 
chromogen is added, the intensity of which is proportional to concentration of antibody 
present the result of which is report in optical density (OD).The maximum optical density 
result is reported is 3.5, and stronger signals are reported as >3.5. Based on in-house 
laboratory practice, this result determines, whether reflex p24, western blot or HIV viral load 
tests will be done. 
The Abbott Realtime® HIV-1 assay is a real time PCR assay that detects HIV viral load in 
plasma samples (Abbott Molecular 2011). The assay is able to quantify virus over a range of 
40 to 107 RNA copies per ml plasma. Absence of detected virus is reported as lower than 
detectable (LDL). For the purposes of this study, samples that are greater than LDL but with 
a result of less 1000 RNA copies/ml were regarded as equivocal and greater than 1000 RNA 
copies were regarded as positive.  
In order to confirm primary HIV infection, the VIDAS®HIV P24 II was used. This sandwich 
immunoassay detects the p24 antigen by fluorescence (BioMerieux 2010). Samples are 
regarded as positive if reported as greater than 5 pg/ml. The maximum result reported is 400 
pg/ml; stronger signals are reported as >400 pg/ml.  
The qualitative BIO-RAD GS HIV-1 Western Blot was used to detect and identify antibodies 
to HIV in human serum and plasma (Biorad 2013). HIV-1 specific antibody binds to HIV 
antigen fixed onto a nitrocellulose membrane. A colour change reaction allows for the 
identification of bound antibody. The position and intensity of the bands are compared to the 
reference strips. The WHO criteria for HIV-1 western blots positivity were used to determine 
results. The criteria require 2 ENV bands (gp160, gp120, gp41), while POL (p66, p51, p32) 
and GAG (p55, p40, p24, p17) bands may be present but not required for a positive result. 
Negative samples do not have bands and indeterminate samples have profiles that do not fit 
the positive or negative criteria (WHO 1991).  
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2.3  Test flow  
All samples were screened using the 4th generation HIV ELISA assay and confirmed with 
the 3rd generation ELISA as part of routine test flow. If the confirmatory test was negative, 
both the p24 assay (routinely) and HIV viral load was performed (as part of the study in 
which additional tests were performed in order to compare the standard practice of 
performing p24 only initially; with performing the HIV viral load test which was thought to 
potentially be an improved practice). If both screening and confirmation results were low 
positives weakly reactive, an HIV viral load was performed. If the HIV viral load result 
produced was lower than detectable level of the assay or less than 1000 RNA copies/ml, the 
sample was tested using the western blot assay (see figure 1). If the result was greater than 
1000 copies/ml it was regarded as a positive sample and no further testing was done. If the 
western blot was positive, the sample was regarded as positive. If the western blot result 
was negative, the result was considered indeterminate and clinician was asked to send a 
new sample. 
2.3.1 Gold standard for true positives  
True positive samples had an HIV viral load ≥ 1000 RNA copies/ml or an HIV viral load < 
1000 RNA copies/ml with conclusive western blot, otherwise were regarded as false positive 




Figure 1. Flow diagram to determine the gold standard for HIV positive samples. Both p24 and the HIV viral load were 
performed when the HIV confirmatory results was negative because of uncertainty of the correct strategy.  
2.4 Interpretation and statistical analysis  
Statistical analysis was performed using statistical software Stata (version 11.1, StataCorp, 
Texas, USA) and Graphpad Prism (version 6.03, San Diego, USA). Continuous variables 
were summarised using median and interquartile ranges and categorical variables were 
analysed as proportions/ percentages with 95% confidence intervals with binomial 
distribution. The sensitivity, specificity, positive (PPV) and negative predictive values (NPV) 
of the assays were determined using 2X2 tables. Non-parametric Spearman’s correlation 
was used to determine correlation. Receiver Operating Characteristic (ROC) analysis was 
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performed and the optimal cut-off for the HIV chemiluminescent-based screening assay was 
determined as a means to predict a true positive result. 
 
3. Results 
3.1 Patients  
The median age of patients included in the study was 30 years old (IQR: 26-43); 29 (60%) 
were women; none of the samples were follow-up samples from the same patient as follow-
up samples were not available.  
3.2 Assay results  
Of the 18423 samples screened using the 4th generation ELISA assay, 13213 (71.7%) were 
negative, 5123 were true positives and 87 were indeterminate or low positive. Forty-eight 
samples fulfilled the inclusion criteria and were included in the analysis. An additional 39 
samples had a S/CO of less than 20 but had insufficient sample left to perform the 
confirmatory 3rd generation ELISA assay and therefore did not fulfil the inclusion criteria. 
The 48 samples had all been screened for HIV using the 4th generation ARCHITECT (®) 
HIV Ag/Ab Combo assay. The median of the semiquantative relative light units produced 
was 6.92 S/CO (IQR: 2.4-15.31 S/CO). Twenty samples of 48 were positive when tested 
using Enzygnost® Anti-HIV 1/2 plus. The median O.D. of the samples deemed to be 
negative was 0.04 and was 1.56 OD for the samples deemed to be true positives. Forty-five 
samples were tested for HIV RNA using the Abbott Realtime® HIV-1 assay. Twenty two 
samples had detectable virus and 23 did not have detectable virus. Twenty-four samples 
were tested for the p24 antigen using the VIDAS®HIV P24 II assay; 22/24 were negative. 
Six samples had the BIO-RAD GS HIV-1 Western Blot performed, all of which were positive. 
Twenty-four samples were classified as true positives. 
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3.3 Statistical Analysis  
3.3.1 Sensitivity and specificity  
For the 48 samples that were tested, the sensitivity of the 3rd generation HIV confirmatory 
assay was 72% while the specificity was 91%. The PPV of this assay was 90% and the NPV 
was 75% in this weakly reactive or discrepant serology population. For the 24 samples that 
had the p24 test performed, the sensitivity of the assay was 37% and the specificity was 
100%. The NPV and PPV of this assay was 100% and 72%, respectively. The sensitivity of 
the 3rd generation ELISA assay (72%) and that of the p24 assay (37%) compared poorly to 
HIV viral load when it is used as the gold standard. Only 6 samples were had the western 
blot test performed as determined by the gold standard criteria. The sensitivity, specificity, 
PPV and NPV of the western blot assay in this context was 100%. 
3.3.2 Correlation  
Despite a significant correlation between 4th and 3rd generation ELISA tests (Rho 0.3589, 
p= 0.0012); and 4th generation and HIV viral load tests (Rho 0.4860, p=0007), when plotting 
the 4th generation screening value on the x-axis against the 3rd generation confirmatory or 
against the HIV viral load value on the y-axis, it appears difficult to predict the respective 
confirmatory 3rd generation and HIV viral load result relative to the screening result (see 
figure 2 and table 2). Eighty-four percent of samples with confirmatory ELISA OD values 
above 0.5 had detectable viral loads and there were clearly two subgroups of viral load 
results reported as either lower than the detectable limit (LDL) or greater than 4 log10(figure 
2). The single exception was the result of 3.95 log10. Similar to the screening / confirmatory 
result comparison, there were two clear subgroups of viral load results reported; either LDL 
or greater than 4log10. Of the samples that had the p24 antigen test performed and had 
detectable HIV viral load (range: 4-5 log10), only 28% had a p24 antigen detected. These p24 
results ranged between 20 and 30 pg/ml. 
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Table 2. Spearman’s correlation of the 4th generation screening values and the 3rd generation confirmatory and HIV 
viral load values. The 0.3589 and the 0.4860 shows correlation between the between the 4th generation screening results and 
the 3rd generation confirmatory and HIV viral load, respectively. (Data generated in Graphpad Prism version 6.03, San Diego, 
USA) 
3.3.3.  ROC analysis  
Figure 2. Comparison of the ELISA and HIV viral 
load results. a. Screening 4th generation HIV 
ELISA results compared with log10 HIV viral load. 
b.Screening 4th generation compared with 
confirmatory 3rd generation ELISA results. c. 
Comparison of the confirmatory 3rd generation 
ELISA results and log10 HIV viral load results. 
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Results from all the assays underwent Receiver Operating Characteristic (ROC) analysis. 
The most significant result was that of the 4th generation HIV ELISA screening test. As 
shown in figure 3 and table 3, samples with a S/CO ratio of greater than 3.19 should be 
considered as true positive in this sample set, as according to the ROC analysis, using this 
value as the a cut-off of 3.19 will result in the most correctly classified results (83%). The 
area under the curve was 0.8035.The specificity at this cut-off was poor at 65%. By using a 
higher cut-off, the specificity can be improved but at the cost of sensitivity (see 
supplementary data for full table). At a cut-off of 17.93, the specificity is 100% but the 














 (>= 1.1) 100.00% 0.00% 52.08% 
(>= 3.19) 100.00% 65.22% 83.33% 
(>= 17.93) 20.00% 100.00% 58.33% 
(> 19.68) 0.00% 100.00% 47.92% 
  
 
Table 3.Receiver Operating 
Characteristic (ROC) analysis for 
the 4th generation HIV ELISA 
screening test used in the 
diagnosis of HIV infection. The 
cut-off point of 3.19 was shown to 
correctly classify the highest number 
of results. Sensitivity was 100% at 
this point but specificity was 65.22%. 
A cut point of 17.93 results in 
specificity of 100% but the sensitivity 
was only 56%. See appendix for full 
table. 
Figure 3. The diagrammatic representation of 
the ROC curve analysis for the HIV 4th 
generation ELISA screening test.  
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4.  Discussion  
The 4th generation HIV ELISA used in this study lacked specificity when looking at this 
dataset of samples with S/CO <20, and therefore confirms WHO guidelines that confirming 
positive screening results with a highly specific set of assays will be valuable. For this 
sample group, the 3rd generation HIV confirmatory assay had better specificity (91%) than 
sensitivity (72%), as is required of a confirmatory assay. The 91% specificity reflects the two 
false positive tests in the dataset. The positive predictive value of this confirmatory assay 
was 90% which was an indication that the majority of cases detected as positive were truly 
positive. However, according to the NPV, only 75% of samples were correctly classified as 
negative. The p24 assay lacked sensitivity but the positive predictive value of 100% 
confirmed that a positive result in this study is truly positive. The lack of sensitivity raises the 
question of whether the p24 assay should be used as a screening tool for acute HIV 
infection in this setting. The HIV viral load assay proved to be the best option for confirmation 
of problematic serology in this laboratory as the sensitivity, specificity, PPV and NPV were 
ideal. Therefore, if a sample in this laboratory has low positive screening and confirmation 
results, or discrepant screening and confirmatory serology, these results deem the HIV viral 
load as the best option to most likely to confirm HIV status in problematic cases. 
A major finding of the study was that screening value of 3.19 S/CO was the cut-off that 
determined whether the result was truly positive or not. In this sample set of low positive 
screening tests, any value above this cut-off was more likely to be correctly classified as a 
true positive in 83% of cases but would still require additional tests to confirm positivity. The 
area under the curve of 0.8 suggests that this test has good discriminatory value as a 
diagnostic test and therefore can be used as a screening test. However, the small sample 
size included in this study probably does not allow for these findings to be transferred to all 
laboratories using these assays. It does, however, allow for recommendations that can 
advise staff in this laboratory when faced with difficulty while interpreting HIV serology 
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results. The ROC‘s main contribution is to show that each laboratory needs to determine its 
own “greyzone” in order to guide further testing.  
The ROC result for suspecting true positive 4th generation ELISA screening results was 
quite low and this will certainly impact the threshold at which pathologists will request 
additional tests, particularly the viral load, in order to determine true HIV status. 
The HIV viral load assay was the best additional confirmatory assay with excellent sensitivity 
and specificity, but this was probably due to the pre-determined criteria of a true positive 
result. Furthermore, as mentioned in the results, there was a clear distinction between 
negative and positive viral loads and the positive viral load results were high. However using 
the HIV viral load test as a confirmatory test will be of limited diagnostic value in patients 
who are elite controllers as they will not have virus detectable by current assays (Bello et al. 
2009). 
The p24 lacked sensitivity at 37% thereby confirming previous publications of low sensitivity 
(Daar et al. 1999; Barletta et al. 2004; Pascual et al. 2002). Daar et al documented the 
sensitivity of p24 antigen at 88.7%. Barletta et al. quoted that the antigen was detected in 
only 50% of acute infections, while Pascual et al. produced positive results in only 65% of 
samples with viral loads between 1000-10000 RNA copies/ml. Our study detected only 28% 
of samples with viral loads above 4 log10.This low sensitivity, in addition to the negative 
predictive value of 72%, supports additional the additional HIV viral load requests in cases 
where the result is negative, and acute infection is still suspected. Therefore the question is 
whether the p24 assay should be still be performed or whether the cost of doing both assays 
for a number of cases will be cheaper than doing the viral loads for confirmation for all low 
positive and discrepant results.  
In our study 87/ 18423 total samples required additional tests In a simple costing calculation 
it was assumed that all samples will have a screening and a confirmatory assay performed, 
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and if discrepant, a p24 and an HIV viral test would follow. The p24 test and HIV viral load 
costs the client R161.88 and R305.61, respectively (see table 1). By doing both the client will 
be charged an additional R467.49. By doing just the HIV viral load the client will save 
R161.88 per patient. Therefore, based on this study, confirming the HIV status of uncertain 
samples (after screening and confirmation ELISAs) with the HIV viral load will be a cost 
saving measure in our laboratory The p24 takes less time to perform than the HIV viral load, 
but it is the current laboratory practice to batch these samples in order to save cost of assay 
controls. Therefore the turnaround time of the p24 may be longer the than the HIV viral load 
which, although the assay takes longer to perform, is performed every day. However, it is 
possible to perform the assay for just one sample in urgent cases which cannot be done for 
HIV viral load. In the future, when faster and single feed viral load platforms become 
available, performing urgent viral loads should probably no longer be problematic. An assay 
that would be able to distinguish between antigen and antibody would assist in solving this 
issue as well. This will potentially be an upgrade of the current 4th generation assay to a 5th 
generation ELISA, i.e. an assay that detects both antigen and antibody with differentiation. 
Weakly reactive HIV screening results may be true positives. The low positive 4th generation 
HIV ELISA results may reflect a variation of the so-called “second window period” that has 
been detected in this assay class reflecting a time point when p24 antigen has declined but 
the antibody is still below the level of detection of the assay.The detection of acute HIV is 
dependent on the sensitivity of the p24 component and for the ARCHITECT (®) HIV Ag/Ab 
Combo it has been shown to detect p24 at 58 000 RNA copies/ml (Brennan et al. 2013).This 
may be the explanation for high viral loads associated with low screening values. Patients 
may be undiagnosed HIV elite controllers with positive serology and undetectable HIV viral 
loads (Vermeulen et al. 2013). Some elite controllers have been shown to mimic newly 
infected individuals with low antibody responses and poor avidity (Bello et al. 2009). Patients 
infected with HIV-2 may be mistakenly diagnosed as having false positive serology as 
current HIV viral load assays in use in South Africa detect only HIV-1. A high index of 
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suspicion must be held for this possibility in cases where persistently positive HIV serology is 
accompanied by persistently negative viral load results. 
The HIV confirmatory assay had two false positive results as reflected by the specificity of 
91%. As discussed earlier in the manuscript, there are a multitude of clinical conditions that 
can result in the production of false positive HIV serology results. In my experience, false 
positive results usually have low ODs and are western blot and HIV viral load negative. They 
can be differentiated from acute infection where the viral load is high 
It is questionable whether performing the western blot assay added value. The sample size 
was small. The western blot assay was only performed in cases where there are antibodies 
in the sample, i.e. the 3rd generation confirmatory assay is weakly reactive. Therefore it was 
not of use in cases where acute infection was suspected based on the screening and 
confirmatory results (56% of our dataset). However, there are western blot seroconversion 
profiles that are based on the total number of positive bands present but these bands do not 
make up a full banding pattern and therefore do not give a clear positive result (Hecht et all, 
2011). Performing the assay requires training, and with multiple manual steps being present, 
it is quite time-consuming. The results are that are produced are sometimes difficult to 
interpret and are reported as indeterminate in those cases (Cárdenas et al. 2013). The aim 
of the study was to streamline the process of troubleshooting difficult results by developing a 
validated HIV testing protocol. The aforementioned factors limit the use of the western blot in 
a potential algorithm. However, it may still have role when all other tests are inconclusive, 
antibodies have been detected in the samples, and one has easy access to a laboratory 
performing the assay. 
The quantitative HIV DNA assay was not included in this study as the assays used in this 
study and in routine HIV screening are performed on serum or plasma samples. The 
package insert of the HIV DNA test states that the sample type of choice is whole blood. The 
purpose of the test is for early infant testing (SOP GPL2192) and therefore not within the age 
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group of patients at whom the algorithm is aimed. The assay also, in pathologists’ 
experience, lacks sensitivity which may have compromised the aim of the study.  
Comparing the quantitative HIV viral load assay with semiquantative assays may be 
regarded as limitation but it is acceptable to compare the quantitative HIV viral load with 
semiquantative diagnostic tests when it is being interpreted as a semiquantative diagnostic 
test. 
The result of this type of analysis may be altered in different sample sets. This study may be 
regarded as a “pilot” study. A prospective study with a larger sample size and sufficient 
sample volume required to perform all the assays assessed in this study may produce a 
different cut-off value. Performing this analysis in a community with a different HIV 
prevalence may affect the outcome of ROC analysis as well i.e. if the prevalence was lower, 
the ROC cut-off for the 4th generation EIA may be higher. 
It is a limitation of this study that the history of each patient was not reviewed but this was a 
laboratory-based study and therefore beyond its scope. By reviewing the history, it would 
have been possible to exclude the abovementioned clinical causes. It would also have been 
useful to know the history when determining true positives as it would have been possible to 
exclude samples from known HIV positive patients erroneously sent for serology, resulting in 
misleading serology and HIV viral load results. It is acceptable to compare the quantitative 
HIV viral load with semiquantative diagnostic tests when it is being interpreted as a 
semiquantative diagnostic test. 
It is imperative that clinicians are closely involved with interpretation and management of 
difficult HIV serology results. Consultation with clinicians will result in pathologists having 
access to more in-depth histories than is written on most clinical request forms thereby 
allowing them to make more informed decisions when analysing results. The importance of 
sending new specimens for additional tests, particularly in cases where sample volumes are 
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initially insufficient for extra tests, or allowing for a certain time period to elapse after initial 
tests are inconclusive to allow potential development of conclusive results, needs to be 
clearly conveyed to clinicians in order to negate potential poor follow-up and thereby allow 
patients access to treatment as soon as possible. Unfortunately South Africa has a low 
doctor to patient ratio, 0.77 per 1000 as compared to the UK and Australia where the ratio is 
2.3 and 2.47 per 1000 respectively (B Strachan et al. 2011). Seeing many patients and 
therefore not being able to remember individual patients in order to follow up results could 
possibly a reason for poor responses to requests for additional samples. 
 
5.  Conclusion 
This study illustrates the importance of validation of assays with samples from the local 
population in each individual laboratory. Cost of the assay, the number of samples requiring 
confirmation, the HIV prevalence and subtype composition in the local population, staff skill 
and turnaround time should all be determining factors when recommending assay for a 
particular laboratory setting. We have found that that using the HIV viral load as confirmatory 
assay for discrepant and weakly reactive or low positive serology samples is the best 
strategy in our laboratory as the results are reliable and it is economically viable. The results 
of this study concur with the new CDC guidelines in suggesting the HIV viral is the optimal 
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Appendix A: Full Received Operating Analysis table 
 
Table. Full Receiver Operating Characteristic (ROC) analysis for the 4th 
generation HIV ELISA screening test used in the diagnosis of HIV in this 
study. 
 
Appendix B: CDC HIV diagnostic algorithm 
 
Source: Centers for Disease Control and Prevention (CDC). Detection of acute 
HIV infection in two evaluations of a new HIV diagnostic testing algorithm - 






Appendix C: HPA diagnostic algorithm 
 
Source: Health Protection Agency. (2012). Anti-HIV Screening. UK Standards for 
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Appendix D: South African recommended serial HIV testing algorithm 
 
Source: National Department of Health, 2010. National HIV Counselling and 
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accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author,
or to rearrange the author names, must be sent to the Journal Manager from the corresponding author
of the accepted manuscript and must include: (a) the reason the name should be added or removed,
or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that
they agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed. Requests that are not sent by
the corresponding author will be forwarded by the Journal Manager to the corresponding author, who
must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal
Editors of any such requests and (2) publication of the accepted manuscript in an online issue is
suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange
author names in an article published in an online issue will follow the same policies as noted above
and result in a corrigendum.
Copyright
This journal offers authors a choice in publishing their research: Open Access and Subscription.
For Subscription articles
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for
more information on this and copyright, see http://www.elsevier.com/copyright). An e-mail will be
sent to the corresponding author confirming receipt of the manuscript together with a 'Journal
Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations
(please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are
included, the author(s) must obtain written permission from the copyright owners and credit the
source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult
http://www.elsevier.com/permissions.
For Open Access articles
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License
Agreement' (for more information see http://www.elsevier.com/OAauthoragreement). Permitted
reuse of open access articles is determined by the author's choice of user license (see
http://www.elsevier.com/openaccesslicenses).
Retained author rights
As an author you (or your employer or institution) retain certain rights. For more information on
author rights for:
Subscription articles please see
http://www.elsevier.com/journal-authors/author-rights-and-responsibilities.
Open access articles please see http://www.elsevier.com/OAauthoragreement.
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Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in
journals published by Elsevier, to comply with potential manuscript archiving requirements as specified
as conditions of their grant awards. To learn more about existing agreements and policies please visit
http://www.elsevier.com/fundingbodies.
Open access
This journal offers authors a choice in publishing their research:
Open Access
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An Open Access publication fee is payable by authors or their research funder
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our access programs (http://www.elsevier.com/access)
• No Open Access publication fee
All articles published Open Access will be immediately and permanently free for everyone to read
and download. Permitted reuse is defined by your choice of one of the following Creative Commons
user licenses:
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create
extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article
(such as a translation), to include in a collective work (such as an anthology), to text or data mine
the article, even for commercial purposes, as long as they credit the author(s), do not represent the
author as endorsing their adaptation of the article, and do not modify the article in such a way as
to damage the author's honor or reputation.
Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-
commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and
other revised versions, adaptations or derivative works of or from an article (such as a translation),
to include in a collective work (such as an anthology), to text and data mine the article, as long as
they credit the author(s), do not represent the author as endorsing their adaptation of the article, do
not modify the article in such a way as to damage the author's honor or reputation, and license their
new adaptations or creations under identical terms (CC BY-NC-SA).
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-
commercial purposes, lets others distribute and copy the article, and to include in a collective work
(such as an anthology), as long as they credit the author(s) and provided they do not alter or modify
the article.
To provide Open Access, this journal has a publication fee which needs to be met by the authors or
their research funders for each article published Open Access.
Your publication choice will have no effect on the peer review process or acceptance of submitted
articles.
The publication fee for Open Access in this journal is $1,800, excluding taxes. Learn more about
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
language and language services
Please write your text in good English (American or British usage is accepted, but not a mixture
of these) avoid the use of split infinitives, and do not use the first person pronoun. Authors
who require information about language editing and copyediting services pre- and post-submission
please visit http://www.elsevier.com/languageediting  or our customer support site at http://
epsupport.elsevier.com for more information.
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Submission
Submission to this journal proceeds totally online and you will be guided stepwise through the creation
and uploading of your files. The system automatically converts source files to a single PDF file of the
article, which is used in the peer-review process. Please note that even though manuscript source
files are converted to PDF files at submission for the review process, these source files are needed for
further processing after acceptance. All correspondence, including notification of the Editor's decision
and requests for revision, takes place by e-mail removing the need for a paper trail.
Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of three potential
referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers
are used.
PREPARATION
Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text
should be in single-column format. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. In particular, do not use the word
processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts
(see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Note that
source files of figures, tables and text graphics will be required whether or not you embed your figures
in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. The Results and
Discussion section must be written separately. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
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• Author names and affiliations. Where the family name may be ambiguous (e.g., a double name),
please indicate this clearly. Present the authors' affiliation addresses (where the actual work was
done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after
the author's name and in front of the appropriate address. Provide the full postal address of each
affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that phone numbers (with country and area
code) are provided in addition to the e-mail address and the complete postal address.
Contact details must be kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial
form designed to capture the attention of a wide readership online. Authors must provide images
that clearly represent the work described in the article. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. See http://www.elsevier.com/graphicalabstracts for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images also in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey
the core findings of the article and should be submitted in a separate file in the online submission
system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85
characters, including spaces, per bullet point). See http://www.elsevier.com/highlights for examples.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Avoid the excessive use of abbreviations in the text and do not use unconventional acronyms.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Nomenclature and units.
Follow internationally accepted rules and conventions: use the international system of units (SI). If
other quantities are mentioned, give their equivalent in SI.
Virus nomenclature.
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Each virus should be identified at least once, preferably in the 'Introduction' or 'Materials and Methods'
section, using formal family, genus, and species terms and where possible by using a precise strain
designation term as developed by an internationally recognized specialty group or culture collection.
Please note that the word type is not used before species designations that include a number. Formal
terms used for virus families, genera, and species should be those approved by the International
Committee on Taxonomy of Viruses (ICTV):Fauquet, C.M., Mayo, M.A.,Maniloff, J., Desselberger, U.,
and Ball, L.A.(2005) Virus Taxonomy, Classification and Nomenclature of Viruses. Eighth ICTV Report,
Academic Press, an imprint of Elsevier. This volume also includes standard abbreviations for species.
Once formal taxonomic names have been given in a paper, vernacular terms may be used.
Formal taxonomic nomenclature
In formal taxonomic usage, the first letters of virus order, family, subfamily, genus and species
names are capitalized and the terms are printed in italics. Other words in the species names are not
capitalized unless they are proper nouns or parts of nouns, for example West Nile virus. In formal
usage, the name of the taxon should precede the term for the taxonomic unit; for example; "the
family Paramyxoviridae," "the genus Morbillivirus." The following represent examples of full formal
taxonomic terminology:
Order Mononegavirales, family Rhabdoviridae, genus Lyssavirus, species Rabies virus. Family
Poxviridae, subfamily Chordopoxvirinae, genus Orthopoxvirus, species Vaccinia virus. Family
Picornaviridae, genus Enterovirus, species Poliovirus. Family Bunyaviridae, genus Tospovirus, species
Tomato spotted wilt virus.
Vernacular Taxonmic Nomenclature
In formal vernacular usage, virus order, family, subfamily, genus and species names are written in
lower case Roman script: they are not capitalized, nor are they printed in italics or underlined. In
informal usage, the name of the taxon should not include the formal suffix, and the name of the taxon
should follow the term for the taxonomic unit; for example "the picornavirus family, the enterovirus
genus." One particular source of ambiguity in vernacular nomenclature lies in the common use of
the same root terms in formal family, genus or species names. Imprecision stems from not being
able to easily identify in vernacular usage which hierarchical level is being cited. For example, the
vernacular name "paramyxovirus" might refer to the family Paramyxoviridae, or one species in the
genus Respirovirus, such as Human parainfluenza virus 1. The solution in vernacular usage is to avoid
"jumping" hierarchical levels and to add taxon identification wherever needed. For example, when
citing the taxonomic placement of Human parainfluenza virus 1, taxon identification should always be
added: Human Parainfluenza virus 1 is a species in the genus Respirovirus, family Paramyxoviridae.
In this example, as is usually the case, adding the information that this virus is also a member of the
subfamily Paramyxovirinae and the order Mononegavirales is unnecessary.
It should be stressed that italics and capital initial letters need be used only if the species name
refers to the taxonomic category. When the name refers to viral objects such as virions present in
a preparation or seen in an electron micro
Database linking
Elsevier encourages authors to connect articles with external databases, giving their readers one-
click access to relevant databases that help to build a better understanding of the described research.
Please refer to relevant database identifiers using the following format in your article: Database: xxxx
(e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See http://www.elsevier.com/databaselinking
for more information and a full list of supported databases.
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article, using
superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may
be used. Should this not be the case, indicate the position of footnotes in the text and present the
footnotes themselves separately at the end of the article. Do not include footnotes in the Reference
list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.
Artwork
AUTHOR INFORMATION PACK 10 Mar 2014 www.elsevier.com/locate/jviromet 9
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the printed version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in
color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or on the Web only. For further information on the
preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise by converting color figures to 'gray
scale' (for the printed version should you not opt for color in print) please submit in addition usable
black and white versions of all the color illustrations.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables
below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be
sparing in the use of tables and ensure that the data presented in tables do not duplicate results
described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
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journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of
publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first
alphabetically, then chronologically.
Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al.
(2010) have recently shown ....'
List: References should be arranged first alphabetically and then further sorted chronologically if
necessary. More than one reference from the same author(s) in the same year must be identified by
the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci.
Commun. 163, 51–59.
Reference to a book:
Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York.
Reference to a chapter in an edited book:
Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S.,
Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations:
http://www.issn.org/services/online-services/access-to-the-ltwa/.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
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relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum
size of 50 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or
make a separate image. These will be used instead of standard icons and will personalize the
link to your video data. For more detailed instructions please visit our video instruction pages at
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded
in the print version of the journal, please provide text for both the electronic and the print version
for the portions of the article that refer to this content.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words and
to help readers understand what the paper is about. More information and examples are available at
http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation
e-mail to create an AudioSlides presentation after acceptance of their paper.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research.
Supplementary files offer the author additional possibilities to publish supporting applications, high-
resolution images, background datasets, sound clips and more. Supplementary files supplied will be
published online alongside the electronic version of your article in Elsevier Web products, including
ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is
directly usable, please provide the data in one of our recommended file formats. Authors should
submit the material in electronic format together with the article and supply a concise and descriptive
caption for each file. For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Phone numbers
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)
and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black-and-white versions of the figures are also supplied for
printing purposes
For any further information please visit our customer support site at http://support.elsevier.com.
Virology Protocols
Protocols are to be submitted in the same way as regular articles
Organization of a Protocol
Title page:
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The title page should contain the following items: (i) complete title (preferably no chemical formulas
or arbitrary abbreviations); (ii) full names of all authors; (iii) complete affiliations of all authors; (iv)
the number of text pages of the whole manuscript (including figures and tables) and the number
of figures and tables; (v) the name and complete address of the corresponding author (including
telephone number, facsimile number and electronic mail address); (vi) acknowledgements.
Abstract:
This should provide a concise description of the purpose of the Protocol and should not exceed 200
words.
Keywords:
Please provide 3 - 6 keywords.
Type of research:
In this section, relevant published studies should be described concisely in list form preceded by
Roman lower case numeral characters. The published studies should be appropriately cited.
Time required.
An estimation of the time required to run the protocol should be given per separate step and for
the whole protocol.
Materials
The materials used should be described in sufficient detail for the protocol to be replicated. Animals
used should include information on breed, breeder, sex, age, weight and the maintenance conditions.
Furthermore, this section should be divided into two subsections: (i) Special equipment and (ii)
Chemicals and reagents. Any special equipment required should be mentioned, including details of
model type/number and (international) supplier. The source or supplier of any special equipment
should also be stated, in parentheses, after mentioning the equipment for the first time. A listing
(preceded by dashes) of chemicals and reagents used in the protocol, should be provided, if applicable.
Special chemicals and drugs with their sources or suppliers should be grouped under a separate
subheading ("Chemicals" or "Drugs"). For drugs, generic names should be used; trade names may be
given in brackets where the drug is first mentioned. In case of new drugs or chemicals, a full chemical
description (formula) should be given. The form of the drug used should be indicated.
Detailed procedure.
This section should include an extensive, detailed and stepwise description of the procedures used.
The individual steps should be described in list form preceded by Roman lower case numeral characters
and correspond with the steps described under Quick procedure. All companies from which chemicals
or materials were obtained should be listed with their full address.
Results.
In this section the expected results should be described clearly and concisely, and in logical order
without extended discussion of their significance. Results should usually be presented descriptively
and be supplemented by photographs or diagrams.
Discussion.
This section should present an assessment of the protocol, problems which may be encountered, and
alternative or support protocols.This section should be divided into two parts: (i) Trouble-shooting and
(ii) Alternative and Support Protocols. Troubleshooting: Problems that may have been encountered
during any of the procedures should be discussed clearly and concisely, and suitable solutions
suggested. Alternative methods for replacing certain steps in the protocol should be mentioned in
sufficient detail, and clearly indicating at which point in the protocol they should be applied.Alternative
and Support Protocols: If applicable, alternative or support protocols should be mentioned, clearly
stating the advantages and disadvantages of such protocols and be accompanied by appropriate
citation of the literature.
Essential literature references.
This should mention certain essential reading divided into original papers, book chapters and review
papers. Do not cite the full reference, but just list the reference number. All references cited in the text
should be listed at the end of the manuscript, arranged in alphabetical order of the author's surname.
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Quick procedure.
This section should describe the protocol in a concise, stepwise manner. The individual steps should
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